Major Improvement in the Efficacy of BRCA1 Mutation Screening Using Morphoclinical Features of Breast Cancer

Rosette Lidereau, François Eisinger, Marie-Héléne Champêmè, Catherine Nougès, Ivan Biéche, Daniel Birnbaum, Claude Pallud, Jocelyne Jacqumenier, and Hagay Sobol

Unit of Cancer Molecular Genetics/Institut National de la Santé et de la Recherche Médicale (INSERM) EPI 00317 (R. L., M-H. C., C. N., I. B.), and Department of Pathology (C. P.), René Huguenin Center, 92210 Saint-Cloud, France; Department of Genetic Oncology/INSERM EPI 9939 (F. E., J. J., H. S.), Laboratory of Tumor Biology (D. B., J. J., H. S.), and Department of Pathology (J. J.), Paoli-Calmettes Institute, 13273 Marseille Cedex 9, France; and INSERM U 119, 13009 Marseille, France (D. B.)

Abstract

A family history of breast and/or ovarian cancer is the main criterion used in screening BRCA1 gene carriers. However, ascertaining a patient’s family history is a difficult task, which significantly restricts the use of this parameter in clinical practice. Alternative individual criteria that can be used to identify BRCA1 gene carriers would, therefore, be of great value. In this context, it was recently established that BRCA1-associated breast cancers (BRCA1-BCs) show a specific morphoclinical pattern. In multivariate analyses, the two most discriminant morphoclinical parameters available for establishing the BRCA1 status, in addition to an early age at onset, are estrogen receptor negativity (ER−) and poor tumor differentiation (TD3). Here we tested the efficacy of these two morphological parameters as BRCA1 mutation indicators and investigated their economic impact, in a population-based survey on a series of women who developed invasive breast cancer by the age of 35 years, regardless of their family history. A high rate of 28.6% of BRCA1 mutations was found to have occurred in the group of tumors with both ER− and TD3 versus only 3.6% in tumors with other profiles (P = 0.007; odds ratio, 10.8). When the sole criterion used was early onset by the age of 35 years, the mutation rate was found to be 8.6%. The resulting cost of testing only women with ER− and TD3 tumors worked out at 30% that of testing the whole population of women with cancer by the age of 35 years, and the sensitivity was found to be of 66%. Lastly, the family history of ER− and TD3 cases with a BRCA1 mutation was investigated retrospectively, and none of these cases was found to have a particularly extensive family history of breast and/or ovarian cancer. The use of these morphological features of BRCA1-BCs that are currently typed in clinical practice, therefore, provides a helpful and cost-effective tool for those making decisions about genetic screening. This strategy makes it possible to identify gene carriers who would be overlooked using current criteria.

Introduction

Breast carcinoma is the most common type of cancer occurring in women in the Western world. About 1 in 1,000 women develop breast cancer every year in Europe, which corresponds to almost 30,000 new cases every year in France. It is estimated that about 5% of all cases of breast cancer are transmitted as an autosomal dominant genetic trait, and a fairly high proportion of these are associated with a BRCA1 germ line mutation (1). Although this proportion is small, it corresponds in fact to a large population, consisting of about 1,500 new cases every year at the French national level. Specific medical interventions need to be proposed (2) for dealing with this population because of the high penetrance of the disease, the prevalence of bilateral breast cancers, and the associated risk of developing ovarian carcinoma (1). At present, the indications for performing a BRCA1 mutation search are based on the existence of a significant family history of breast and/or ovarian carcinoma, combined or not with early age at cancer onset (3–5). However, in clinical practice, the use of these criteria is substantially restricted. Thus, based on the current indications, it has been estimated that about 500 probands (6) would be tested in France for BRCA1 mutations every year, which is far from the expected number of 1,500 patients. This limitation may be due to at least three reasons: (a) a proportion of the patients from high-risk families do not attend cancer genetic clinics; either they do not feel they are concerned or they are afraid of attending, or they are not referred to these clinics by their physicians; (b) large kindreds are becoming rare in the more highly developed countries (European reproduction rate = 1.8; Ref. 6); and, because a family’s medical history is frequently not available or has not been definitely confirmed, the anamnensis tends to be unreliable (7, 8). For all of these reasons, only 30% of the probands attending cancer genetic clinics fit the current clinical indications (6); (c) there is a lack of common family profile among BRCA1 gene carriers, and the risk of carrying a germ line mutation is not limited to the members of families with a history of breast cancer (4, 9–11).

To overcome these obstacles and to improve the efficacy of genetic screening, several options may be envisaged. As far as the lack of attendance at the cancer genetic clinics is concerned, although respecting people’s right to privacy means that no pressure can be placed directly on the members of a family, it is possible to improve physicians’ knowledge about the clinical indications and DNA testing by providing specific training and information (12). However, this still leaves us with the problem of the family structure. Determining alternative individual criteria that can be used to identify BRCA1 gene carriers would certainly be extremely useful, especially if these criteria are both accessible and ascertainable and do not involve obtaining confidential medical data about relatives to establish a family’s genetic background. Interestingly, it has by now been clearly established that BRCA1-associated breast cancers show a specific morphoclinical profile (13–16) that is potentially associated with a particular natural history (14, 17) and makes these cancers distinguishable from their sporadic counterparts as well as from other hereditary cases (18, 19). In addition, multivariate analyses were performed to select the most discriminant features among the numerous differences observed; these features, namely, estrogen receptor negativity (ER−) and TD3 of the tumor (20–22), could thus be taken to have a high predictive

Received 9/1/99; accepted 1/18/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the René Huguenin Center, the Paoli-Calmettes Institute, Assistance Publique de Marseille, and INSERM and by grants from La Ligue Nationale contre le Cancer (the National Office and the District committees of Essonne, Hauts de Seine, Bouches du Rhône, and Var), Association pour la Recherche sur le Cancer, and Fédération Nationale des Centres de Lutte contre le Cancer.

2 To whom requests for reprints should be addressed, at Department of Genetic Oncology/INSERM EPI 9939, Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex 9, France. Phone: 33-491-22-35-40; Fax: 33-491-22-35-04; e-mail: sobo@marseille.insERM.fr.

3 The abbreviations used are: ER−, ER negativity; ER, estrogen receptor; TD, tubular differentiation; OR, odds ratio; CI, confidence interval; TD3, poor TD.
value for establishing the \( BRCA1 \) status. The expected benefit of using these parameters regardless of the family history was calculated. Although the probability of finding a \( BRCA1 \) mutation was found to be low (6%; Ref. 4) on the sole basis of early onset up to the age of 35 years, the theoretical detection rate increased considerably to between 9% and 37% when the steroid receptor negativity and differentiation status were both taken into account (20). However, this strategy still requires testing on a population-based series of cases. With a view to confirming the usefulness of morphochlinical parameters of this kind and to explore the feasibility of using them in a clinical context to orientate DNA screening procedures, we searched for \( BRCA1 \) mutations in a set of 70 consecutive cases of women affected with breast cancer by the age of 35 years without having any prior knowledge of the family history, using the ER status and the differentiation of the tumor as criteria.

**Patients and Methods**

**Patients.** To evaluate the potential value of morphochlinical parameters for \( BRCA1 \) screening, a series of almost consecutive cases of women with invasive breast cancer was constituted from the René Huguenin hospital registry. This registry contains 5700 consecutive cases of primary breast cancer in which the initial treatment was surgery, and information was available about the age at onset, ER status, and TD status, as defined previously (20). The women in whom the onset occurred by the age of 35 years amounted to 3.3% of all of the breast cancer cases. They included 70 women selected because of the availability of a biological sample (tumor and/or lymphocyte DNA) on which a \( BRCA1 \) mutation search could be performed (Table 1). In six cases, a \( BRCA1 \) disease-associated mutation (a mutation leading to a truncation of the protein, or a missense mutation in the ring finger motif; Table 2 (23)) was found. In the remaining 64 cases no proven disease-associated mutation was found in the \( BRCA1 \) gene using the current methods and conditions (24); consequently, they were considered as non-gene carrier patients. These 64 cases included 5 patients with a \( BRCA1 \) sequence variation usually taken to be a polymorphism, i.e., not considered as a disease-associated mutation, (3 missense mutations in the coding sequence other than those observed in the ring finger motif, and 2 cases with variations in an intronic region; Table 2), and, therefore, most of them are listed in the BIC (Breast Cancer Information Core) database\(^4\) as relatively common polymorphisms. All of the 70 cases were diagnosed between January 1980 and December 1996. Our research protocol obtained an institutional review board approval.

**\( BRCA1 \) Mutation Analysis.** Genomic DNA from women with breast cancer by the age of 35 years was prepared directly from tumor samples using a standard procedure. In addition, whenever a mutation was identified, analyses were performed on blood-cell DNA when available, prepared according to a standard procedure. To identify \( BRCA1 \) germ line mutations, DNA automated fluorescent sequencing analysis was performed on both DNA strands after denaturing gradi-

---


\(^5\) Internet address: http://www.myriad.com/gtpat20.html; released on 08/12/99.

---

**Table 1** Distribution of the 70 women with breast cancer diagnosed by the age of 35 years in terms of \( BRCA1 \) mutations status, ER status, and tumor differentiation.

<table>
<thead>
<tr>
<th>Genetic status</th>
<th>ER− and TD3 (%)</th>
<th>Other (%)</th>
<th>Total (%)</th>
<th>( P^a )</th>
<th>OR(^b) (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( BRCA1 )-disease-association mutation</td>
<td>4 (28.6)</td>
<td>2 (3.6)</td>
<td>6 (8.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No ( BRCA1 )-disease-associated mutation</td>
<td>10 (71.4)</td>
<td>54 (96.4)</td>
<td>64 (91.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>14</td>
<td>56</td>
<td>70</td>
<td>0.007</td>
<td>10.8 (1.28–127.7)</td>
</tr>
</tbody>
</table>

\(^a\) \( P \) was calculated by Fisher’s exact two-tailed test.

\(^b\) OR was computed using Mantel-Haenszel inference with the StatXact package (Cytel Software corporation).

---
Among the five cases with BRCA1 sequence variations corresponding to polymorphisms, none were ER− or TD3, which supports their nonpathogenic value (Table 2).

Distribution of BRCA1 Cases in Terms of the Family History. The family history of the cases associated with a BRCA1 germ line mutation and the bilateral occurrence of the breast cancer were investigated retrospectively (Table 2). Among the four ER− and TD3 cases with a BRCA1 germ line mutation, one case (T1) did not have any family history of breast cancer, and two had a short family history, involving only one case of breast cancer in a first- or a second-degree relative (T2: the mother had breast cancer at the age of 48 years; T3: a maternal aunt had breast cancer at the age of 47 years). Only one patient had two first-degree relatives with breast cancer (T4: a sister had breast cancer at the age of 44 years, and the mother had bilateral breast cancer at the age of 37 and 42 years). None of these patients had a personal or family history of ovarian cancer. Lastly, two patients had bilateral metachronous breast cancer (T3: at the age of 29 and 41 years; T4: at 33 and 45 years).

Among the two cases with a BRCA1 mutation and a different morphological profile, the family history of one patient (T5) had not been documented, and the remaining case had an extensive family history of breast cancer (T6: a sister with breast cancer at the age of 40 years, the mother, and the grandmother with onset at an unknown age) and had bilateral breast cancer with onset at the age of 34 years and 40 years.

Among the five cases associated with BRCA1 polymorphisms (Table 2): (a) two (T8, T11) did not have any family history of breast cancer; (b) in one (T9), the family history had not been documented; and (c) two had an irrelevant family history of breast cancer (T7: the mother with unknown age at onset; T10: a maternal aunt with unknown age at onset).

Cost-effectiveness Benefit Ratio of BRCA1 Testing Strategies On the basis of ER Status and Tumor Differentiation. Assuming the overall distribution of cases in France to be that reflected in the René Huguenot hospital registry (20), about 1000 (3.3%) new cases of breast cancer are diagnosed every year by the age of 35 years in France. On the basis of our sample, 20% (20 women) of all these patients will have a tumor which is both ER− and TD3. On the basis of a unit price of $1,200.00 United States dollars per patient, if BRCA1 testing is performed on these 200 women, the resulting cost will be $240,000.00 United States dollars, as compared with $960,000.00 United States dollars in the case of those with a different tumor pattern (800 cases harboring a cancer with only ER− or TD3, or neither), and $1,200,000.00 United States dollars in the whole population of women with breast cancer by the age 35 years (1,000 patients). The respective estimated cost of each mutation detected would be of $4,200.00 United States dollars in the case of the group with a tumor which is both ER− and TD3; $34,000.00 United States dollars in the case of the group with another profile; and $14,000.00 United States dollars in the whole population of women with a breast cancer by the age of 35 years, with a sensitivity of 66% (four of six mutations detected).

Discussion

In clinical practice, cancer geneticists frequently have to face the difficult task of ascertaining the family history of their consultants. Even when there exists a true family history of cancer, there are legal obstacles to obtaining confirmation of the diagnosis from the medical records. In addition, the information about cancer risks conveyed by patients to their relatives is not always very reliable (28). On the other hand, a genetic predisposition can exist in the absence of any obvious genetic background, not only in the rare cases of proven de novo mutation (9), but more often in cases where the inheritance occurs via the father’s family branch or when mutations are associated with a reduced penetrance (11, 29, 30). All of these factors, in addition to the low reproduction rate of families in the Western world, significantly reduce the efficacy of the family history as the main parameter for establishing the genetic status of patients.

In addition, because of the low mutation-detection rate in the populations now under study (4, 31) using current screening methods and because of the resulting cost, performing DNA testing on the general population is not worthwhile. A BRCA1 mutation search is usually envisaged in situations in which there is a high probability of finding a mutation, i.e., large families with a convincing history of early-onset breast and/or ovarian cancer that amount to only a small fraction of the kindreds attending cancer genetic clinics (6).

However, it is of the utmost importance to make appropriate care management procedures available to potential gene carriers. This

---

Table 2 Clinical presentation of tumors associated with disease-associated germ line mutations and sequence variations of the BRCA1 gene from the panel of 70 women with breast cancer by the age of 35 years

<table>
<thead>
<tr>
<th>Tumors</th>
<th>Breast cancer onset</th>
<th>ER status</th>
<th>TD status</th>
<th>BRCA1 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-associated mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>34</td>
<td>ER−</td>
<td>TD3</td>
<td>ex11 g4113T/ggA→TgA ter1332</td>
</tr>
<tr>
<td>T2a,b</td>
<td>29</td>
<td>ER−</td>
<td>TD3</td>
<td>ex17 5149 delCTAA ter1678</td>
</tr>
<tr>
<td>T3a,b</td>
<td>29</td>
<td>ER−</td>
<td>TD3</td>
<td>ex2 185 delAG ter39</td>
</tr>
<tr>
<td>T4a,b</td>
<td>33</td>
<td>ER</td>
<td>TD3</td>
<td>ex11 3957 delCTC ter1280</td>
</tr>
<tr>
<td>T5</td>
<td>35</td>
<td>ER−</td>
<td>TD2d</td>
<td>ex11 g3867T/gAg→TAg ter 1250</td>
</tr>
<tr>
<td>T6b</td>
<td>34</td>
<td>ER+</td>
<td>TD1</td>
<td>ex20 5382 insC ter1829</td>
</tr>
<tr>
<td>Sequence variations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T7</td>
<td>33</td>
<td>ER+</td>
<td>TD2</td>
<td>in20+1-23 ins12</td>
</tr>
<tr>
<td>T8</td>
<td>35</td>
<td>ER+</td>
<td>TD2</td>
<td>in23+1-21 insT</td>
</tr>
<tr>
<td>T9</td>
<td>34</td>
<td>ER+</td>
<td>TD2</td>
<td>ex11 g3143A Met1008Ile</td>
</tr>
<tr>
<td>T10</td>
<td>34</td>
<td>ER</td>
<td>TD2</td>
<td>ex15 g465T Ser152Ile</td>
</tr>
<tr>
<td>T11</td>
<td>35</td>
<td>ER</td>
<td>TD2</td>
<td>ex11 A4158g Arg1347Gly</td>
</tr>
</tbody>
</table>

Family history of

<table>
<thead>
<tr>
<th>Breast cancer (yr of age)</th>
<th>Ovarian cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mother (48)</td>
<td>None</td>
</tr>
<tr>
<td>Maternal aunt (47)</td>
<td>None</td>
</tr>
<tr>
<td>Sister (44)</td>
<td>None</td>
</tr>
<tr>
<td>Mother (37, 42)</td>
<td>None</td>
</tr>
<tr>
<td>Sister (40)</td>
<td>None</td>
</tr>
<tr>
<td>Grandmother</td>
<td>None</td>
</tr>
</tbody>
</table>

* BRCA1 analysis performed in both tumor and lymphocyte DNA.
* Patients who developed a metachronous bilateral breast cancer.
* TD2, occasional or medium TD; TD1, throughout or high TD.
* Age at onset unknown.
means that new parameters are needed to help to identify those with a high risk of developing breast and/or ovarian carcinoma. In this connection, it was recently predicted that individual morphological parameters might prove to be useful tools of establishing the BRCA1 status. In a recent study, we established that the differentiation and ER status of tumors are efficient indicators for identifying BRCA1 gene carriers (20). In the present study, we tested the efficacy and the feasibility of this strategy. A low overall mutation rate of 8.6% was detected in our sample of women with invasive breast cancer by the age of 35 years; whereas, 28.6% of the women with a tumor that was both ER– and TD3 had a BRCA1 germ line mutation, regardless of the family history. For the sake of comparison and to show the validity of our strategy, this observed mutation detection rate can be said to lie in between that obtained up to now when there was a family history of breast cancer only (7–18%; Refs. 24, 31, 32) and when there was a family history of both breast and ovarian cancer (33–67%; Refs 24, 31, 32).

Other features, such as the syncytial growth pattern (16, 19) or the level of the estrogen responsive gene pS2 expression (22), may be valid indicators of BRCA1-associated breast cancer, but these parameters are not always routinely explored and/or they require the intervention of highly trained pathologists. Contrary to the method applied in other analyses (16, 19), our method relies only on the use of common parameters that are easily accessible and currently typed in clinical practice. Thus, the ER and differentiation status of tumors are highly informative parameters that are currently used to establish the prognosis of the disease and to select the appropriate initial therapeutic strategy. Knowledge of these parameters should also be useful to those making decisions about the appropriate initial therapeutic strategy. Knowledge of these parameters is a cost-effective strategy. The cost of testing only women with cancer by the age of 35 years; whereas, 28.6% of the women with a tumor that was both ER– and TD3 had a BRCA1 germ line mutation, regardless of the family history. For the sake of comparison and to show the validity of our strategy, this observed mutation detection rate can be said to lie in between that obtained up to now when there was a family history of breast cancer only (7–18%; Refs. 24, 31, 32) and when there was a family history of both breast and ovarian cancer (33–67%; Refs 24, 31, 32).

Acknowledgments

We are particularly indebted to the patients and their families who participated in this study. We are grateful to Professors D. Maraninchi, J-F. Mattei, J. Roussé, and Drs. C. Mawas, T. Noguchi, and R. Sauvan for helpful discussions and comments.

References


Major Improvement in the Efficacy of *BRCA1* Mutation Screening Using Morphoclinical Features of Breast Cancer

Rosette Lidereau, François Eisinger, Marie-Hélène Champême, et al.


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/5/1206

Cited articles  This article cites 29 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/5/1206.full.html#ref-list-1

Citing articles  This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/60/5/1206.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.